Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$32.76 - $39.56 $16.5 Million - $19.9 Million
502,472 Added 1240.7%
542,971 $19 Million
Q4 2023

Feb 13, 2024

BUY
$14.5 - $38.0 $587,235 - $1.54 Million
40,499 New
40,499 $1.54 Million
Q4 2022

Feb 14, 2023

BUY
$20.18 - $33.33 $165,617 - $273,539
8,207 New
8,207 $202,000
Q2 2022

Aug 15, 2022

BUY
$8.52 - $25.26 $339,735 - $1.01 Million
39,875 New
39,875 $453,000

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $617M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.